GlobeNewswire·Nov 9, 2026, 4:05 PM ET

Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

Maze Therapeutics completed enrollment in the Phase 2 HORIZON trial of MZE829 with over 50 patients across three cohorts, exceeding targets of 10-15 patients per group.
Final data from the HORIZON trial for MZE829 in APOL1-mediated kidney disease (AMKD) is expected in early 2027 to inform a pivotal trial planned for the first half of 2027.
Enrollment is ongoing for the Phase 2 CIPheR trial of MZE782 in phenylketonuria (PKU), with topline data anticipated in 2027.
A Phase 2 trial for MZE782 in chronic kidney disease (CKD) is on track to initiate in the first half of 2027.
Cash, cash equivalents, and marketable securities totaled $477 million as of September 30, 2026, providing a runway into 2029.
License revenue recognized was $20 million for the nine months ended September 30, 2026, resulting from a milestone achievement with Shionogi regarding MZE001.
Research and development expenses increased to $109.3 million for the nine months ended September 30, 2026, driven by clinical program progression.
General and administrative expenses rose to $36.8 million for the nine months ended September 30, 2026, due to higher personnel costs.
Net loss for the nine months ended September 30, 2026, was $116.9 million, or $2.02 per share, compared to $96.6 million for the same period in 2025.
Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., were appointed to the Board of Directors in August 2026.